Clinical Trials Logo

Post-ET MF clinical trials

View clinical trials related to Post-ET MF.

Filter by:
  • None
  • Page 1

NCT ID: NCT03895112 Completed - Clinical trials for Primary Myelofibrosis

MPN-RC 118 AVID200 in Myelofibrosis

Start date: February 15, 2019
Phase: Phase 1
Study type: Interventional

Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-β1 and TGF-β3. The study team hypothesizes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. Patients must have intermediate-2 or higher primary myelofibrosis (PMF), post-essential thrombocythemia or polycythemia-vera related MF (Post ET/PV MF). This study will enroll up to 24 patients. AVID200 is delivered by IV infusion on day 1 of each 3 week cycle.

NCT ID: NCT01644110 Active, not recruiting - Clinical trials for Primary Myelofibrosis

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

POMINC
Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.